508203-26-7

Upstream product

• 132794-07-1 4-chloro-2,5-difluoro-benzoic acid 
• 132794-08-2 2,5-difluoro-4-chlorobenzoyl chloride 

Downstream Products

• 764648-58-0 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6-methylpyrimidine 
• 764648-59-1 4-chloro-2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidine 
• 1395553-38-4 C₂H₂O₄*C₁₈H₁₅ClF₂N₄O 
• 764649-63-0 (2R)-3-{[2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidin-4-yl]amino}propane-1,2-diol oxalate 
• 1395553-37-3 2-(4-chloro-2,5-difluorophenyl)-6-methyl-N-[2-(1-oxidopyridin-3-yl)ethyl]pyrimidin-4-amine 
• 1395552-89-2 2-(4-chloro-2,5-difluorophenyl)-N-[2-(2-methoxypyridin-4-yl)ethyl]-6-methylpyrimidin-4-amine 
• 1395552-94-9 2-(4-chloro-2,5-difluorophenyl)-6-ethyl-N-[2-(2-methoxypyridin-4-yl)ethyl]pyrimidin-4-amine 
• 794485-71-5 4-(2-{[2-(4-chloro-2,5-difluorophenyl)-6-methylpyrimidin-4-yl]amino}ethyl)pyridin-2(1H)-one 
• 795266-61-4 4-(2-{[2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidin-4-yl]amino}ethyl)pyridin-2(1H)-one 
• 764649-62-9 (2R)-3-{[2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidin-4-yl]amino}propane-1,2-diol 
• 135748-35-5 4-chloro-2,5-difluoro-benzonitrile 
• 764648-44-4 4-chloro-2,5-difluorobenzamidine 
• 764648-49-9 2-(4-chloro-2,5-difluorophenyl)-6-methylpyrimidin-4-one 
• 764648-50-2 2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidin-4-one 

Relevant academic research and scientific papers

2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS

Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): (IA) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists

Novel 4-amino-2-phenylpyrimidine derivatives were synthesized and evaluated as GPR119 agonists. Optimization of the substituents on the phenyl ring at the 2-position and the amino group at the 4-position led to the identification of 3,4-dihalogenated and